多模态认知刺激计划改善了泰国轻度认知障碍老年人的认知和生活质量:一项随机对照试验
Phenphichcha Chuchuen1,2, Chavit Tunvirachaisakul3,4,5, Phot Dhammapeera6
1Faculty of Psychology, Chulalongkorn University, Bangkok, Thailand, phenphichcha.psyche@gmail.com.
Dementia and geriatric cognitive disorders
|July 14, 2025
概括
一个为期八次的多模态认知刺激计划 (MCSP) 显著改善了泰国老年轻度认知障碍 (MCI) 的认知和生活质量. 这种非药物干预为管理认知衰退提供了一个有希望的方法.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
背景情况:
- 轻度认知障碍 (MCI) 是一个重要的全球健康问题,特别影响泰国的老年人,增加痴呆风险.
- 非药物干预对于管理认知衰退和提高老年人群的生活质量 (QOL) 至关重要.
- 多模态认知刺激计划 (MCSP) 在以前的研究中已经显示出对认知增强的有效性.
研究的目的:
- 评估八次MCSP对泰国老年人诊断患有MCI的认知功能和QOL的有效性.
- 将MCSP干预组的结果与接受标准护理的对照组进行比较.
主要方法:
- 一项随机对照试验,涉及66名泰国老年患有MCI的老年人,分为干预 (n=32) 或对照 (n=34) 组.
- 认知评估包括迷你精神状态检查 (2002年泰国版),建立阿尔茨海默氏病电池注册表的联盟,色迹测试和数字跨度. 使用QOL-AD尺度衡量生活质量.
- 主要组件分析汇总了认知得分. 协同变量分析 (ANCOVA) 用于分析干预对认知和QOL的影响,控制基线得分和人口因素.
主要成果:
- 与对照组相比,MCSP干预组在整体认知功能 (p=0.033) 和QOL (p=0.017) 中呈现出统计学上显著的改善.
- 安科瓦发现,群体分配,性别,年龄,教育水平和基线分数是认知和质量生活结果变化的重要预测因素.
- 认知和QOL的效果大小 (ηp2) 分别为0.076和0.094,表明干预的影响中等.
结论:
- 八个会话的MCSP是一种有效的非药物干预,用于改善MCI的泰国老年人的认知功能和QOL.
- 这些发现支持使用MCSP作为一种有价值的策略,以缓解认知衰退并提高这一群体的福祉.
- 综合认知评估和验证的QOL测量证实了MCSP干预的好处.
相关概念视频
01:30Cognitive Development During Adulthood
289
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
289
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
212
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
212
01:22Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263